Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
0.9400
+0.0103 (1.11%)
At close: Apr 23, 2025, 4:00 PM
0.9500
+0.0100 (1.06%)
After-hours: Apr 23, 2025, 6:31 PM EDT
Esperion Therapeutics Employees
Esperion Therapeutics had 304 employees as of December 31, 2024. The number of employees increased by 64 or 26.67% compared to the previous year.
Employees
304
Change (1Y)
64
Growth (1Y)
26.67%
Revenue / Employee
$1,093,138
Profits / Employee
-$170,214
Market Cap
185.98M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
ESPR News
- 13 days ago - Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025 - GlobeNewsWire
- 22 days ago - Esperion Appoints Robert E. Hoffman to Board of Directors - GlobeNewsWire
- 7 weeks ago - Esperion Therapeutics, Inc. (ESPR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Esperion Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 7 weeks ago - Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia - GlobeNewsWire
- 2 months ago - Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4 - GlobeNewsWire
- 2 months ago - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions - GlobeNewsWire